Intravenous (IV) belimumab was approved for children ages 5 years to 17 years with active, seropositive SLE receiving standard care.

Earlier this year, the Food and Drug Administration (FDA) approved Symdeko (tezacaftor/ivacaftor) tablets for the treatment of certain cystic fibrosis (CF) patients 12 years and older.

Auvi-Q (epinephrine injection) now comes in 0.1 milligram (mg) strength for patients who weigh 7.5 to 15 kilograms (kg) (16.5 to 33 pounds).